Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$5.02 USD
0.00 (0.00%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $5.03 +0.01 (0.20%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Vanda Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 193 | 254 | 269 | 248 | 227 |
Cost Of Goods | 15 | 24 | 26 | 23 | 24 |
Gross Profit | 178 | 230 | 243 | 225 | 203 |
Selling & Adminstrative & Depr. & Amort Expenses | 192 | 224 | 201 | 198 | 180 |
Income After Depreciation & Amortization | -14 | 6 | 42 | 27 | 23 |
Non-Operating Income | 20 | 5 | 0 | 4 | 6 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 6 | 11 | 42 | 32 | 29 |
Income Taxes | 4 | 5 | 9 | 8 | -87 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 3 | 6 | 33 | 23 | 116 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 3 | 6 | 33 | 23 | 116 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -20 | 6 | 47 | 30 | 23 |
Depreciation & Amortization (Cash Flow) | -6 | 0 | 4 | 3 | 0 |
Income After Depreciation & Amortization | -14 | 6 | 42 | 27 | 23 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 57.56 | 56.98 | 56.92 | 55.19 | 54.85 |
Diluted EPS Before Non-Recurring Items | 0.04 | 0.11 | 0.58 | 0.42 | 2.11 |
Diluted Net EPS (GAAP) | 0.04 | 0.11 | 0.58 | 0.42 | 2.11 |
Fiscal Year end for Vanda Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 50.47 | 47.46 | 45.27 | 38.82 | 46.06 |
Cost Of Goods | 2.73 | 3.44 | 3.46 | 3.06 | 3.50 |
Gross Profit | 47.74 | 44.02 | 41.81 | 35.75 | 42.56 |
SG&A, R&D, and Dept/Amort Expenses | 57.88 | 53.26 | 48.90 | 41.75 | 45.43 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.14 | -9.24 | -7.09 | -6.00 | -2.87 |
Non-Operating Income | 4.63 | 4.57 | 5.43 | 5.88 | 5.46 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -5.52 | -4.66 | -1.66 | -0.12 | 2.59 |
Income Taxes | -1.00 | -0.52 | 0.74 | -0.26 | 1.07 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -4.52 | -4.15 | -2.40 | 0.14 | 1.52 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -4.52 | -4.15 | -2.40 | 0.14 | 1.52 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 58.22 | 57.76 | 57.53 | 57.60 | 57.54 |
Diluted EPS Before Non-Recurring Items | -0.08 | -0.07 | -0.04 | 0.00 | 0.03 |
Diluted Net EPS (GAAP) | -0.08 | -0.07 | -0.05 | 0.00 | 0.03 |